Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA

被引：0
|
作者：
Decker, Thomas
Brucker, Cosima
Engel, Anne
Fasching, Peter A.
Goehler, Thomas
Jackisch, Christian
Janssen, Jan
Koehler, Andreas
Luedtke-Heckenkamp, Kerstin
Lueftner, Diana
van Mackelenbergh, Marion
Marme, Frederik
Nusch, Arnd
Rautenberg, Beate
Reimer, Toralf
Schmidt, Marcus
Weide, Rudolf
Wimberger, Pauline
Roos, Christian
Woeckel, Achim
机构：
[1] Onkol Ravensburg, Ravensburg, Germany
[2] Paracelsus Med Univ, Univ Womens Hosp, Nurnberg, Germany
[3] Winicker Norimed GmbH, Nurnberg, Germany
[4] Univ Hosp Erlangen, Dept Obstet & Gynecol, Erlangen, Germany
[5] Onkozentrum Dresden Freiberg, Dresden, Germany
[6] Sana Klinikum Offenbach, Dept Obstet & Gynecol, Offenbach, Germany
[7] Med Studiengesell Nord West GmbH, Westerstede, Rhauderfehn, Germany
[8] Practice Hematol & Oncol, Langen, Germany
[9] Niels Stensen Kliniken, Dept Hematol & Oncol, Georgsmarienhutte, Germany
[10] Med Univ Brandenburg, Immanuel Klin Markische Schweiz, Buckow, Germany
[11] Univ Klinikum Schleswig Holstein, Kiel, Germany
[12] Heidelberg Univ, Med Fak Mannheim, Mannheim, Germany
[13] Practice Hematol & Internal Oncol, Velbert, Germany
[14] Univ Klinikum Freiburg, Freiburg, Germany
[15] Univ Klinikum Rostock, Rostock, Germany
[16] Johannes Gutenberg Univ Mainz, Klin & Poliklin Geburtshilfe & Frauengesundheit, Mainz, Germany
[17] InVO GbR, Koblenz, Germany
[18] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Dresden, Germany
[19] Novartis Pharma GmbH, Nurnberg, Germany
[20] Univ Wurzburg, Dept Gynecol & Obstet, Wurzburg, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13050
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) + ribociclib (RIB)
    Slamon, D. J.
    Neven, P.
    Chia, S.
    Fasching, P. A.
    De Laurentiis, M.
    Im, S-A.
    Petrakova, K.
    Bianchi, G. V.
    Esteva, F. J.
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    De la Cruz-Merino, L.
    Beck, J. T.
    Pivot, X.
    Sondhi, M.
    Wang, Y.
    Chakravartty, A.
    Rodriguez-Lorenc, K.
    Jerusalem, G.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Ribociclib (RIB) plus letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
    De laurentiis, M.
    Ring, A.
    Campone, M.
    Bachelot, T.
    Jacot, W.
    Marchetti, P.
    Timcheva, C.
    De Valk, B.
    Gombos, A.
    Menon-Singh, L.
    Wu, J.
    Zhou, K.
    Neven, P.
    ANNALS OF ONCOLOGY, 2019, 30 : 117 - +
  • [23] Alpelisib (ALP) plus fulvestrant (FUL) in hormone-receptor positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Subgroup analysis by presence of visceral metastasis (VM) in the SOLAR-1 trial
    Campone, M.
    Rugo, H. S.
    Rubovszky, G.
    Andre, F.
    Loibl, S.
    Iwata, H.
    Conte, P. F.
    Mayer, I.
    Juric, D.
    Yamashita, T.
    Lorenzo, I.
    Ridolfi, A.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2019, 30 : 122 - +
  • [24] Longitudinal circulating tumor DNA (ctDNA) analysis in the phase 1b MONALEESASIA study of ribociclib (RIB) plus endocrine therapy (ET) in Asian patients (pts) with hormone receptor-positive (HR plus )/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC)
    Yap, Y. S.
    Su, F.
    Joshi, M.
    Chiu, J.
    Masuda, N.
    Ito, Y.
    Ishikawa, T.
    Aruga, T.
    Kim, S. J.
    Deore, U.
    Babbar, N.
    Balbin, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S459 - S460
  • [25] Everolimus plus exemestane for hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (BC): overall survival results from BOLERO-2
    Piccart, M.
    Hortobagyi, G. N.
    Campone, M.
    Pritchard, K. I.
    Noguchi, S.
    Rugo, H.
    Gnant, M.
    Feng, W.
    Taran, T.
    Baselga, J.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S1 - S1
  • [26] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC) and central nervous system metastases: Subgroup analysis of the phase IIIb CompLEEment-1 trial
    Cottu, Paul
    De Laurentiis, Michelino
    Marchetti, Paolo
    Coltelli, Luigi
    Califaretti, Nadia
    Debled, Marc
    Patil, Shekar
    Evron, Ella
    Duhoux, Francois
    Menon-Singh, Lakshmi
    Wu, Jiwen
    Zhou, Katie
    Bofill, Javier Salvador
    CANCER RESEARCH, 2021, 81 (04)
  • [27] ECONOMIC ANALYSIS OF COMBINATION THERAPY WITH ALPELISIB AND FULVESTRANT FOR TREATMENT OF HORMONE RECEPTOR-POSITIVE (HR plus ) AND HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED BREAST CANCER
    Delevry, D.
    Le, Q. A.
    VALUE IN HEALTH, 2020, 23 : S32 - S33
  • [28] CompLEEment-1: Phase 3b study of ribociclib plus letrozole for the treatment of hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in patients with no prior endocrine therapy (ET) for ABC
    De Laurentiis, M.
    Martin Jimenez, M.
    Ring, A.
    Cottu, P.
    Zhou, K.
    Wu, J.
    Zarate, J. P.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Safety and efficacy of ribociclib (RIBO) plus letrozole (LET) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study
    De laurentiis, M.
    Mazza, M.
    Mansutti, M.
    Masetti, R.
    Ballatore, Z.
    Torrisi, R.
    Michelotti, A.
    Zambelli, A.
    Ferro, A.
    Generali, D.
    Vici, P.
    Coltelli, L.
    Fabi, A.
    Marchetti, P.
    Ballestrero, A.
    Spazzapan, S.
    Frassoldati, A.
    Sarobba, G.
    Grasso, D.
    Zamagni, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [30] Ribociclib (RIB) plus tamoxifen (TAM) or a non-steroidal aromatase inhibitor (NSAI) in premenopausal women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): additional results from the MONALEESA-7 trial
    Harbeck, N.
    Vazquez, R. Villanueva
    Tripathy, D.
    Lu, Y.
    De Laurentiis, M.
    Kuemmel, S.
    Taylor, D.
    Bardia, A.
    Hurvitz, S.
    Chow, L.
    Im, S.
    Franke, F.
    Hughes, G.
    Miller, M.
    Kong, O.
    Chandiwana, D.
    Colleoni, M.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S3 - S3
12345